UroGen Pharma Ltd. (URGN)
NASDAQ: URGN · Real-Time Price · USD
46.96
+1.36 (2.98%)
At close: Aug 7, 2026, 4:00 PM EDT
47.12
+0.16 (0.34%)
After-hours: Aug 7, 2026, 7:55 PM EDT
UroGen Pharma Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 79.13 | 110.75 | 171.99 | 95 | 55.41 | 44.36 |
Short-Term Investments | 28.84 | 9.71 | 64.7 | 41.97 | 44.56 | 44.78 |
Cash & Short-Term Investments | 107.98 | 120.46 | 236.69 | 136.97 | 99.96 | 89.14 |
Cash Growth | -31.21% | -49.11% | 72.80% | 37.02% | 12.14% | -12.62% |
Accounts Receivable | 88.76 | 33.08 | 20.3 | 15.44 | 12.7 | 11.72 |
Inventory | 24.59 | 16.46 | 9.23 | 5.67 | 4.33 | 4.83 |
Other Current Assets | 14.11 | 16.02 | 9.92 | 11.1 | 11.91 | 8.7 |
Total Current Assets | 235.43 | 186.02 | 276.14 | 169.19 | 128.91 | 114.39 |
Net Property, Plant & Equipment | 8.23 | 9.09 | 3.79 | 2.36 | 3.75 | 3.15 |
Long-Term Investments | - | - | 5.02 | 4.5 | - | 0.68 |
Other Long-Term Assets | 8.94 | 5.34 | 0.77 | 2.26 | 2.96 | 1.53 |
Total Assets | 252.59 | 200.46 | 285.71 | 178.31 | 135.62 | 119.75 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 39.95 | 27.72 | 27.43 | 16.54 | 12.38 | 12.1 |
Accrued Expenses | 12.25 | 13.52 | 10.57 | 10.81 | 8.26 | 6.95 |
Current Portion of Leases | 2.1 | - | - | - | - | - |
Other Current Liabilities | 7.62 | 5.19 | 7.95 | 3.86 | 3.28 | 3.33 |
Total Current Liabilities | 61.92 | 46.42 | 45.95 | 31.21 | 23.92 | 22.38 |
Long-Term Debt | 188.73 | 122.21 | 121.73 | 98.55 | 97.54 | - |
Long-Term Leases | 5.3 | 6.12 | 1.65 | 0.84 | 1.59 | 0.4 |
Other Long-Term Liabilities | 129.04 | 131.18 | 125.18 | 112.92 | 101.94 | 88.56 |
Total Long-Term Liabilities | 323.07 | 259.51 | 248.57 | 212.31 | 201.06 | 88.95 |
Total Liabilities | 384.99 | 305.93 | 294.51 | 243.52 | 224.98 | 111.33 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0.14 | 0.13 | 0.12 | 0.09 | 0.06 | 0.06 |
Additional Paid-in Capital | 865.11 | 854.09 | 797.25 | 614.04 | 487.79 | 475.7 |
Accumulated Other Comprehensive Income | -0 | 0.02 | 0.06 | 0.01 | -0.11 | -0.03 |
Retained Earnings | -997.64 | -959.72 | -806.22 | -679.35 | -577.1 | -467.32 |
Shareholders' Equity | -132.4 | -105.47 | -8.8 | -65.21 | -89.36 | 8.41 |
Total Liabilities & Equity | 252.59 | 200.46 | 285.71 | 178.31 | 135.62 | 119.75 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 196.13 | 128.33 | 123.39 | 99.4 | 99.12 | 0.4 |
Net Cash (Debt) | -88.15 | -7.88 | 113.3 | 37.57 | 0.84 | 88.74 |
Net Cash Growth | - | - | 201.54% | 4367.66% | -99.05% | -11.72% |
Net Cash Per Share | -1.78 | -0.16 | 2.64 | 1.30 | 0.04 | 3.97 |
Book Value | -132.4 | -105.47 | -8.8 | -65.21 | -89.36 | 8.41 |
Book Value Per Share | -2.68 | -2.19 | -0.21 | -2.26 | -3.92 | 0.38 |
Tangible Book Value | -132.4 | -105.47 | -8.8 | -65.21 | -89.36 | 8.41 |
Tangible Book Value Per Share | -2.68 | -2.19 | -0.21 | -2.26 | -3.92 | 0.38 |